By KELIN DILLON
Mexico’s Federal Commission for Protection against Health Risks (Cofepris) approved the emergency use of the vaccine Covaxin on Tuesday, March 6, making it the sixth vaccine to obtain approval for use to inoculate Mexico’s population against covid-19.
Covaxin, which is manufactured in India by pharmaceutical company Bharat Biotech, “meets the quality, safety and efficacy requirements necessary to be applied in Mexico,” said Cofepris.
Interim analysis from the two-shot Covaxin’s phase 3 trials show the vaccine to have 81 percent efficacy against covid-19, though it has yet to reach approval from the World Health Organization (WHO).
Undersecretary of Health Hugo López-Gatell said, despite its approval, Mexico has no plans to bring the Indian-made vaccine into the country at this time.
“It is an interesting vaccine in terms of its efficacy, its safety. It is comparable to the vaccines already authorized in Mexico, which are the five recently presented, and it can contribute to expanding the country’s vaccine portfolio,” said López-Gatell.
“At this time there is no specific plan to acquire this vaccine. However, we have considered that it is pertinent that there are authorization resolutions for emergency use when there is the technical merit of the vaccines. It cannot be marketed in Mexico, it is exclusively for government use.”
Covaxin now joins five other vaccines approved for use in Mexico: AstraZeneca, Pfizer, Sputnik V, CanSino, and Sinovac.
…April 8, 2021